Home
Clinical Trials
GADD34 and Type I IFN Respons...

GADD34 and Type I IFN Response Genes in SLE

NCT ID: NCT03206359

Last Updated: 2017-07-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-25

Study Completion Date

2015-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

GADD34 (Growth Arrest and DNA Damage inducible-protein) is a regulatory subunit of PP1 (phosphatase 1) phosphatase which dephosphorylates eIF2alpha (eucaryotic initiation factor 2 alpha subunit), representing a negative feedback loop of the unfolded protein response (UPR). Moreover, GADD34 is necessary for type I interferon (IFN) production in response to viral infection in murine models. We investigate here the expression of GADD34 in systemic lupus erythematosus (SLE), in which type I IFN has an important pathogenic role.

We report a case-control study on GADD34 gene expression in PBMC (peripheral blood mononuclear cells) of SLE patients (n=60) and age- and sex-matched healthy controls (n=30). The level of GADD34 gene expression, as well as of type-I IFN response genes in PBMC is measured by quantitative PCR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus

NCT02455089

Lupus Erythematosus

COMPLETED NA

A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)

NCT01135459

Systemic Lupus Erythematosus

COMPLETED PHASE2

Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA)

NCT05394922

Lupus Erythematosus Disseminatus Autoimmune Diseases Chronic Disease

RECRUITING

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

NCT01777256

Systemic Lupus Erythematosus

TERMINATED PHASE2

T Regulatory Cells IN LUPUS NEPHRITIS

NCT06428539

Lupus Nephritis

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Patients with SLE

No interventions assigned to this group

Healthy subjects

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man and woman over 18 years old.
* Patients suffering from SLE (SLICC criteria)
* Patients having given their "Non-opposition"
* Patients with social security affiliation (required in France)

Exclusion Criteria

* Patients suffering from other auto-immune disease (except SAPL, thyroiditis, and Gougerot Sjogren syndrome)
* Patients with viral infection within 15 days
* People with special protection (defined in articles L1121-§5-8 and articles L3212-§1-3 of French health care law)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes